Roche Holding AG (SWX:ROG)
341.20
-10.30 (-2.93%)
At close: Mar 6, 2026
Roche Holding AG Revenue
In the year 2025, Roche Holding AG had annual revenue of 63.36B CHF with 1.54% growth. Roche Holding AG had revenue of 31.51B in the half year ending December 31, 2025, with 5.64% growth.
Revenue
63.36B
Revenue Growth
+1.54%
P/S Ratio
4.30
Revenue / Employee
613.62K
Employees
103,249
Market Cap
272.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 63.36B | 961.00M | 1.54% |
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novartis AG | 44.94B |
| Galderma Group AG | 4.16B |
| Lonza Group AG | 6.53B |
| Alcon | 8.25B |
| Sandoz Group AG | 8.85B |
| Straumann Holding AG | 2.61B |
| Sonova Holding AG | 3.85B |
| Galenica AG | 4.03B |
Roche Holding AG News
- 20 hours ago - Roche chairman still expects diagnostics hit from US tariffs - Reuters
- 1 day ago - New England Journal of Medicine publishes phase III ALLEGORY data showing Roche's Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus - GlobeNewsWire
- 1 day ago - New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech's Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus - Business Wire
- 1 day ago - Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial - WSJ
- 2 days ago - Roche's obesity drug shows up to 10.7% weight loss in mid-stage trial - Reuters
- 2 days ago - Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity - GlobeNewsWire
- 2 days ago - Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity - Business Wire
- 2 days ago - New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools - PRNewsWire